![Molecules, microbes and multiomics artwork](https://is2-ssl.mzstatic.com/image/thumb/Podcasts123/v4/2a/46/b6/2a46b600-b6b5-c4f1-d8d4-effc21fead7a/mza_8592612661371652922.png/100x100bb.jpg)
Detection and full genotyping of Human Papillomavirus (HPV) in first-void urine
Molecules, microbes and multiomics
English - June 17, 2020 19:18 - 24 minutes - 34 MB - ★★★★★ - 3 ratingsLife Sciences Science Technology rna dna genomics microbiome multiomics Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: How to ensure the best sequencing results from saliva and fecal samples
Next Episode: Solving the mysteries of your pet’s gut health
We recently had the opportunity to interview Rebecca Millecamps, a Marketing Manager at Fujirebio, a global leader in the field of in vitro diagnostics (IVD). In 2019, Novosanis and Fujirebio, signed a worldwide, non-exclusive agreement for the distribution of Colli-Pee®, Novosanis’ urine collection device for use with Fujirebio’s INNO-LiPA HPV genotyping Extra II assay. This partnership enables detection and full genotyping of Human Papillomavirus (HPV) in first-void urine (first 20 mL of urine) collected with Colli-Pee®. In this podcast, Rebecca discusses how urine testing will impact HPV testing, what the benefits are of performing HPV genotyping in urine samples and the future for urine testing for HPV compared to cervical samples.